Nature Communications (Feb 2017)
Integrated genomic analyses of de novo pathways underlying atypical meningiomas
- Akdes Serin Harmancı,
- Mark W. Youngblood,
- Victoria E. Clark,
- Süleyman Coşkun,
- Octavian Henegariu,
- Daniel Duran,
- E. Zeynep Erson-Omay,
- Leon D. Kaulen,
- Tong Ihn Lee,
- Brian J. Abraham,
- Matthias Simon,
- Boris Krischek,
- Marco Timmer,
- Roland Goldbrunner,
- S. Bülent Omay,
- Jacob Baranoski,
- Burçin Baran,
- Geneive Carrión-Grant,
- Hanwen Bai,
- Ketu Mishra-Gorur,
- Johannes Schramm,
- Jennifer Moliterno,
- Alexander O. Vortmeyer,
- Kaya Bilgüvar,
- Katsuhito Yasuno,
- Richard A. Young,
- Murat Günel
Affiliations
- Akdes Serin Harmancı
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Mark W. Youngblood
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Victoria E. Clark
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Süleyman Coşkun
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Octavian Henegariu
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Daniel Duran
- Yale Program in Brain Tumor Research, Yale School of Medicine
- E. Zeynep Erson-Omay
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Leon D. Kaulen
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Tong Ihn Lee
- Whitehead Institute for Biomedical Research
- Brian J. Abraham
- Whitehead Institute for Biomedical Research
- Matthias Simon
- Department of Neurosurgery, University of Bonn Medical School
- Boris Krischek
- Department of General Neurosurgery, University Hospital of Cologne
- Marco Timmer
- Department of General Neurosurgery, University Hospital of Cologne
- Roland Goldbrunner
- Department of General Neurosurgery, University Hospital of Cologne
- S. Bülent Omay
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Jacob Baranoski
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Burçin Baran
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Geneive Carrión-Grant
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Hanwen Bai
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Ketu Mishra-Gorur
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Johannes Schramm
- Department of Neurosurgery, University of Bonn Medical School
- Jennifer Moliterno
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Alexander O. Vortmeyer
- Department of Pathology, Yale School of Medicine
- Kaya Bilgüvar
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Katsuhito Yasuno
- Yale Program in Brain Tumor Research, Yale School of Medicine
- Richard A. Young
- Whitehead Institute for Biomedical Research
- Murat Günel
- Yale Program in Brain Tumor Research, Yale School of Medicine
- DOI
- https://doi.org/10.1038/ncomms14433
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Meningiomas are mostly benign brain tumours with the potential for becoming atypical or malignant. Here, the authors show that primary atypical meningiomas are epigenetically and genetically distinct from benign and progressed tumours, highlighting possible therapeutic targets such as PRC2.
